AKRX Investor Alert: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals (NASDAQ: AKRX) Investors

Friday, February 9, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, Feb. 9, 2018 /PRNewswire/ --áKyros Law Offices is alerting investors of Akorn Pharmaceuticals (NASDAQ: AKRX) that

it is filing legal claims on behalf of investors against the company for possible securities fraud violations..

Akorn Pharmaceuticals (NASDAQ: AKRX) investors that purchased stock BETWEEN MAY 6, 2014 AND APRIL 24, 2015á are urged to contact our law firm immediately to protect their rights. Visit our

AKRX Shareholder Lawsuit Settlement webpage or call 1-800-934-2921 to speak to someone about your case. Your legal rights will be affected whether you act or do not act. If you do not act, you may permanently forfeit your right to recover on this claim.

Akorn Pharmaceuticals (NASDAQ: AKRX) will pay $24 million to settle a class action lawsuit accusing the company of inflating revenue figures and using faulty accounting practices after a federal judge granted preliminary approval for a deal between the two parties in United States District Court for the Northern District of Illinois, Eastern Division.

Kyros Law Offices urges Akorn Pharmaceuticals (NASDAQ: AKRX) investors to contact our law firm immediately to protect their rights. Visit Akorn Pharmaceuticals (NASDAQ: AKRX) Lawsuit Settlement or call 1-800-934-2921 to find out if you have a case.

Due to the terms of the proposed settlement, your legal rights will be affected whether you act or do not act. If you do not act, you may permanently forfeit your right to recover on this claim.

Kyros Law specializes in a wide range of complex litigation, mass torts, and corporate governance matters, including the representation of whistleblowers, shareholders and consumers in securities fraud, false claims act and class actions. Our lawyers have been responsible for recovering hundreds of millions of dollars for our clients throughout the United States, Africa, Asia and Europe. Visit our website to learn more about our firm.

Cision View original content:http://www.prnewswire.com/news-releases/akrx-investor-alert-kyros-law-is-filing-compensation-claims-on-behalf-of-akorn-pharmaceuticals-nasdaq-akrx-investors-300596403.html

SOURCE Kyros Law



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store